BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh SB, McLearn-Montz AJ, Milavetz F, Gates LK, Fox C, Murry LT, Sabus A, Porterfield HS, Fischer AJ. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. Pediatr Pulmonol 2019;54:1200-8. [PMID: 31012285 DOI: 10.1002/ppul.24341] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Keith JD, Henderson AG, Fernandez-Petty CM, Davis JM, Oden AM, Birket SE. Muc5b Contributes to Mucus Abnormality in Rat Models of Cystic Fibrosis. Front Physiol 2022;13:884166. [PMID: 35574458 DOI: 10.3389/fphys.2022.884166] [Reference Citation Analysis]
2 Durfey SL, Pipavath S, Li A, Vo AT, Ratjen A, Carter S, Morgan SJ, Radey MC, Grogan B, Salipante SJ, Welsh MJ, Stoltz DA, Goss CH, McKone EF, Singh PK. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections. mBio 2021;12:e0314821. [PMID: 34903059 DOI: 10.1128/mbio.03148-21] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
3 Bui S, Masson A, Enaud R, Roditis L, Dournes G, Galode F, Collet C, Mas E, Languepin J, Fayon M, Beaufils F, Mittaine M. Long-Term Outcomes in Real Life of Lumacaftor-Ivacaftor Treatment in Adolescents With Cystic Fibrosis. Front Pediatr 2021;9:744705. [PMID: 34869102 DOI: 10.3389/fped.2021.744705] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Fischer AJ, Singh SB, LaMarche MM, Maakestad LJ, Kienenberger ZE, Peña TA, Stoltz DA, Limoli DH. Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med 2021;203:328-38. [PMID: 32750253 DOI: 10.1164/rccm.202004-1322OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
6 Perveen S, Chaudhry MR, AlBabtain S, Amreen S, Brar SK, Zeb M, Khan S. How Clinically Efficient Is Lumacaftor/Ivacaftor for Cystic Fibrosis Patients? An Updated Literature Review. Cureus 2020;12:e12251. [PMID: 33520477 DOI: 10.7759/cureus.12251] [Reference Citation Analysis]
7 Shrestha CL, Zhang S, Wisniewski B, Häfner S, Elie J, Meijer L, Kopp BT. (R)-Roscovitine and CFTR modulators enhance killing of multi-drug resistant Burkholderia cenocepacia by cystic fibrosis macrophages. Sci Rep 2020;10:21700. [PMID: 33303916 DOI: 10.1038/s41598-020-78817-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ringshausen FC, Hellmuth T, Dittrich AM. [Evidence-based treatment of cystic fibrosis]. Internist (Berl) 2020;61:1212-29. [PMID: 33201261 DOI: 10.1007/s00108-020-00896-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Savant AP, McColley SA. Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatr Pulmonol 2020;55:3236-42. [PMID: 32833326 DOI: 10.1002/ppul.25039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Saiman L. Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol 2019;54 Suppl 3:S18-26. [PMID: 31715086 DOI: 10.1002/ppul.24522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
11 Laucirica DR, Garratt LW, Kicic A. Progress in Model Systems of Cystic Fibrosis Mucosal Inflammation to Understand Aberrant Neutrophil Activity. Front Immunol 2020;11:595. [PMID: 32318073 DOI: 10.3389/fimmu.2020.00595] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Fischer AJ, Kilgore SH, Singh SB, Allen PD, Hansen AR, Limoli DH, Schlievert PM. High Prevalence of Staphylococcus aureus Enterotoxin Gene Cluster Superantigens in Cystic Fibrosis Clinical Isolates. Genes (Basel) 2019;10:E1036. [PMID: 31842331 DOI: 10.3390/genes10121036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]